责任编辑：小浪快报 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 02月04日消息，截止13:20，动力煤板块走强，兖矿能源、中煤能源、晋控煤业涨停，潞安环能、山西 焦煤、山煤国际、恒源煤电、新集能源、平煤股份、中国神华等个股涨幅居前。 ...

Group 1 - The core viewpoint of the news is that TBEA Co., Ltd. has experienced fluctuations in its stock price and significant trading activity, with a notable increase in stock price year-to-date and over recent trading periods [1][2]. - As of February 4, TBEA's stock price decreased by 2.01% to 28.71 CNY per share, with a trading volume of 5.675 billion CNY and a turnover rate of 3.87%, resulting in a total market capitalization of 145.066 billion CNY [1]. - The company has seen a year-to-date stock price increase of 29.21%, with a 2.32% increase over the last five trading days, an 18.69% increase over the last 20 days, and an 8.96% increase over the last 60 days [1]. Group 2 - TBEA's main business segments include electrical equipment products (27.64%), coal products (18.27%), wire and cable products (16.22%), and new energy products and engineering (13.06%) [1]. - As of September 30, TBEA reported a revenue of 72.918 billion CNY for the first nine months of 2025, representing a year-on-year growth of 0.88%, and a net profit attributable to shareholders of 5.484 billion CNY, which is a 27.62% increase year-on-year [2]. - The company has distributed a total of 15.118 billion CNY in dividends since its A-share listing, with 6.591 billion CNY distributed over the last three years [3]. Group 3 - TBEA operates within the power equipment sector, specifically in the sub-sector of transmission and transformation equipment, and is involved in concepts such as transformers, granular silicon, and power IoT [2]. - As of September 30, TBEA had 354,100 shareholders, an increase of 10.92% from the previous period, with an average of 14,268 circulating shares per shareholder, a decrease of 9.84% [2]. - The top three circulating shareholders include Hong Kong Central Clearing Limited, which holds 116 million shares, a decrease of 10.7 million shares from the previous period [3].

Group 1 - The core viewpoint of the news is that 恒瑞医药's stock has experienced a decline, with a 2.00% drop on February 4, 2023, and a year-to-date decrease of 5.46% [1] - As of February 4, 2023, 恒瑞医药's stock price was reported at 56.32 yuan per share, with a total market capitalization of 373.07 billion yuan [1] - The company has seen a net outflow of 1.57 billion yuan in principal funds, with significant selling pressure observed [1] Group 2 - 恒瑞医药, established on April 28, 1997, and listed on October 18, 2000, is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology [2] - The company's revenue composition includes 86.88% from product sales, 12.63% from licensing income, and 0.49% from other sources [2] - As of September 30, 2025, 恒瑞医药 reported a total of 397,300 shareholders, with an average of 16,058 circulating shares per shareholder [3] Group 3 - For the period from January to September 2025, 恒瑞医药 achieved a revenue of 23.188 billion yuan, representing a year-on-year growth of 14.85%, and a net profit of 5.751 billion yuan, up 24.50% year-on-year [3] - The company has distributed a total of 9.303 billion yuan in dividends since its A-share listing, with 3.568 billion yuan distributed in the last three years [4] - As of September 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited and China Securities Finance Corporation, with notable changes in shareholding [4]

2月4日，盈方微盘中下跌2.09%，截至11:05，报8.42元/股，成交2.02亿元，换手率2.90%，总市值71.13 亿元。 资金流向方面，主力资金净流出1868.31万元，特大单买入255.34万元，占比1.27%，卖出1009.13万元， 占比5.00%；大单买入2699.80万元，占比13.38%，卖出3814.31万元，占比18.91%。 盈方微今年以来股价涨14.09%，近5个交易日跌7.27%，近20日涨13.78%，近60日跌0.47%。 截至9月30日，盈方微股东户数13.92万，较上期增加14.05%；人均流通股5868股，较上期减少0.84%。 2025年1月-9月，盈方微实现营业收入34.43亿元，同比增长17.62%；归母净利润-4334.49万元，同比减 少18.69%。 分红方面，盈方微A股上市后累计派现2341.00万元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，盈方微十大流通股东中，国新证券股份有限公司位居第四大流通 股东，持股1220.58万股，相比上期减少839.49万股。香港中央结算有限公司位居第九大流通股东，持股 358.79万股，相比 ...

Group 1 - The methanol concept sector is active, with companies such as Yanzhou Coal Mining, Shanxi Black Cat, and China Coal Energy reaching the daily limit up [1] - Yunnan Coal Energy and Shanxi Coking Coal are among the stocks with significant gains [1]

Group 1 - The SOFC concept sector has seen a significant increase, with companies like Chunhui Zhikong and Shudao Equipment leading the gains [1] - The market is experiencing notable fluctuations, indicating potential investment opportunities within the SOFC sector [1]

责任编辑：小浪快报 02月04日消息，截止09:45，贵州国资板块大涨，贵绳股份等个股涨幅居前。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 ...

2月3日，英集芯涨3.61%，成交额2.48亿元。两融数据显示，当日英集芯获融资买入额2197.49万元，融 资偿还3215.87万元，融资净买入-1018.37万元。截至2月3日，英集芯融资融券余额合计2.87亿元。 分红方面，英集芯A股上市后累计派现1.71亿元。近三年，累计派现1.55亿元。 机构持仓方面，截止2025年9月30日，英集芯十大流通股东中，香港中央结算有限公司位居第七大流通 股东，持股332.07万股，相比上期增加61.41万股。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 融资方面，英集芯当日融资买入2197.49万元。当前融资余额2.87亿元，占流通市值的2.61%，融资余额 超过近一年80%分位水平，处于高位。 融券方面，英集芯2月3日融券偿还1200.00股，融券卖出500.00股，按当日收盘价计算，卖出金额1.26万 元；融券余量1.37万股，融券余额34.75万元，低于近一年50 ...

Group 1 - The core viewpoint of the news is that Jingwei Hengrun's stock performance and financial metrics indicate a mixed outlook, with significant trading activity and a notable increase in revenue but a negative net profit [1][2]. Group 2 - On February 3, Jingwei Hengrun's stock rose by 5.26%, with a trading volume of 493 million yuan. The financing buy-in amount was 35.39 million yuan, while the financing repayment was 39.91 million yuan, resulting in a net financing buy of -4.52 million yuan [1]. - As of February 3, the total financing and securities balance for Jingwei Hengrun was 345 million yuan, with the financing balance at 343 million yuan, accounting for 2.07% of the circulating market value, which is above the 90th percentile level over the past year [1]. - The company has a significant presence in the electronic products sector, with 87.55% of its revenue coming from electronic products, while research services and solutions contributed 12.21% [1]. Group 3 - As of September 30, the number of shareholders for Jingwei Hengrun was 6,719, a decrease of 6.09% from the previous period, while the average circulating shares per person increased by 6.49% to 13,400 shares [2]. - For the period from January to September 2025, Jingwei Hengrun achieved a revenue of 4.464 billion yuan, representing a year-on-year growth of 25.88%. However, the net profit attributable to the parent company was -75.05 million yuan, which is an increase of 81.70% year-on-year [2]. - Notably, as of September 30, 2025, Changcheng Jiujia Innovation Growth Mixed A (004666) exited the list of the top ten circulating shareholders of Jingwei Hengrun [2].

2月3日，泰格医药涨4.97%，成交额10.32亿元。两融数据显示，当日泰格医药获融资买入额5393.21万 元，融资偿还5727.85万元，融资净买入-334.64万元。截至2月3日，泰格医药融资融券余额合计6.31亿 元。 截至9月30日，泰格医药股东户数4.84万，较上期减少6.01%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，泰格医药实现营业收入50.26亿元，同比减少0.82%；归母净利润10.20亿元，同比增长 25.45%。 分红方面，泰格医药A股上市后累计派现24.58亿元。近三年，累计派现11.54亿元。 机构持仓方面，截止2025年9月30日，泰格医药十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股4836.25万股，相比上期增加2509.69万股。中欧医疗健康混合A（003095）位居第四大流 通股东，持股2885.17万股，相比上期增加121.78万股。华宝中证医疗ETF（512170）位居第五大流通股 东，持股1456.80万股，相比上期减少266.25万股。易方达创业板ETF（159915）位居第八大流通股东， 持股1125.86万股，相比上期减少 ...